Mason Carrico
Stock Analyst at Stephens & Co.
(1.75)
# 3,152
Out of 4,858 analysts
81
Total ratings
29.41%
Success rate
-9.1%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Reiterates: Overweight | $67 | $45.70 | +46.61% | 2 | May 22, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $87.98 | +19.35% | 8 | May 20, 2025 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $1.8 | $1.16 | +55.17% | 5 | May 15, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $10.65 | +31.46% | 6 | May 15, 2025 | |
| HOLX Hologic | Maintains: Overweight | $77 → $70 | $65.14 | +7.46% | 4 | May 13, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $19.85 | +101.51% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $95.64 | +20.24% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $27.88 | +61.41% | 7 | Mar 26, 2025 | |
| OCX OncoCyte | Reiterates: Equal-Weight | $4 | $2.80 | +42.86% | 5 | Mar 26, 2025 | |
| GH Guardant Health | Reiterates: Overweight | $55 | $50.09 | +9.80% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3.5 → $1.8 | $1.33 | +35.34% | 6 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $3.47 | +72.91% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $18.17 | -6.44% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $38.87 | +33.78% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $5.24 | +281.68% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $18.04 | +127.27% | 7 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 | $165.22 | -24.34% | 4 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $19 | $7.84 | +142.35% | 1 | Jul 30, 2024 | |
Vericel
May 22, 2025
Reiterates: Overweight
Price Target: $67
Current: $45.70
Upside: +46.61%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $87.98
Upside: +19.35%
Pacific Biosciences of California
May 15, 2025
Reiterates: Overweight
Price Target: $1.8
Current: $1.16
Upside: +55.17%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $10.65
Upside: +31.46%
Hologic
May 13, 2025
Maintains: Overweight
Price Target: $77 → $70
Current: $65.14
Upside: +7.46%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $19.85
Upside: +101.51%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $95.64
Upside: +20.24%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $27.88
Upside: +61.41%
OncoCyte
Mar 26, 2025
Reiterates: Equal-Weight
Price Target: $4
Current: $2.80
Upside: +42.86%
Guardant Health
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $50.09
Upside: +9.80%
Mar 25, 2025
Downgrades: Equal-Weight
Price Target: $3.5 → $1.8
Current: $1.33
Upside: +35.34%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $3.47
Upside: +72.91%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $18.17
Upside: -6.44%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $38.87
Upside: +33.78%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $5.24
Upside: +281.68%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $18.04
Upside: +127.27%
Aug 9, 2024
Reiterates: Overweight
Price Target: $125
Current: $165.22
Upside: -24.34%
Jul 30, 2024
Reiterates: Overweight
Price Target: $19
Current: $7.84
Upside: +142.35%